Recruitment status changed
Before: Completed. After: Terminated.
Among the trials TrialRedline tracks, 63 changed their ClinicalTrials.gov record in January 2026: 5 status changes to terminated, withdrawn or suspended, 21 primary outcome text edits, 14 completion dates moved later, 5 completion dates moved earlier, 23 enrollment changes, 27 other status changes. Each entry shows the previous and updated value and links to the registry's own version comparison.
5 in January 2026. Recruitment status changed to Terminated, Withdrawn or Suspended. Terminated first, then newest.
Before: Completed. After: Terminated.
Before: Active not recruiting. After: Terminated.
Before: Recruiting. After: Terminated.
Before: Completed. After: Terminated.
Before: Active not recruiting. After: Terminated.
21 in January 2026. The text of the main study measures changed. Edits to capitalization, punctuation or spacing alone are left out. Newest first.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Safety and Tolerability as Measured by Number of/Incidence of Treatment-expected Adverse Events (TEAE) and Treatment-related Adverse Events (AEs). Measure: Safety and Tolerability as Measured by Number of/Incidence of Adverse Events of Special Interest and Serious Adverse Events Measure: Safety and Tolerability as Measured in Evaluation of Vital Signs, Clinical Laboratory Results and Findings From Physical, Neurological, Ophthalmological Examinations and Electrocardiograms. Measure: To Evaluate the Long-term Safety and Tolerability of AL002 Utilizing the Columbia-Suicide Severity Rating Scale (C-SSRS) Measure: To Evaluate the Effect of Dose Titration on ARIA-E Measure: To Evaluate the Effect of Dose Titration on ARIA-H. After: Measure: Safety and Tolerability as Measured by Number of Treatment-expected Adverse Events (TEAE) and Treatment-related Adverse Events (AEs). Measure: Safety and Tolerability as Measured by Number of Adverse Events of Special Interest and Serious Adverse Events Measure: Safety and Tolerability as Measured by the Number of Cases of Abnormal Vital Signs, Clinical Laboratory Results and Findings From Physical, Neurological, Ophthalmological Examinations and Electrocardiograms. Measure: To Evaluate the Long-term Safety and Tolerability of AL002 by Assessing Suicidality Using the Columbia-Suicide Severity Rating Scale (C-SSRS) Measure: To Evaluate the Effect of Dose Titration on the Occurrence of ARIA-E Measure: To Evaluate the Effect of Dose Titration on the Occurrence of ARIA-H.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: To assess the effect of PRAX-562 on the frequency of countable motor seizures in pediatric participants with DEEs. After: Measure: PART A (Cohorts 1 and 2) RDB: To evaluate the safety and tolerability of PRAX 562 in pediatric participants with SCN2A- and SCN8A- DEEs Measure: PART B (Cohorts 1 and 2) OLE: To evaluate the long-term safety and tolerability of PRAX-562 in pediatric participants with DEEs.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: [Part A] To evaluate the effect on PVR in participants with WHO Group 1 PAH treated with IKT-001 compared to placebo Measure: [Part B] To characterize the effects of IKT-001 on symptoms and characteristics of Pulmonary Arterial Hypertension compared to placebo. After: Measure: [Part A] To evaluate the effect on Pulmonary Vascular Resistance (PVR) in participants with WHO Group 1 PAH treated with IKT-001 compared to placebo Measure: [Part B] To characterize the effects of IKT-001 on symptoms and characteristics of Pulmonary Arterial Hypertension compared to placebo.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Part 1: Incidence of adverse events (AEs) and serious adverse events (SAEs) Measure: Part 2: Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR) per Response Assessment in Neuro-Oncology (RANO) 2.0. After: Measure: Part 1: Incidence of adverse events (AEs) and serious adverse events (SAEs) Measure: Part 2: Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR) per Response Assessment in Neuro-Oncology (RANO) 2.0 Measure: Part 3 Objective Response Rate (ORR) (Complete Response (CR), Partial Response (PR) and Minor Response (MR)) assessed by Blinded Independent Central Review (BICR) per Response Assessment in Neuro-Oncology (RANO) 2.0.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Slope of Change in 6-Minute Walk Distance (6MWD) Over 72 Weeks. After: Measure: DB Period: Change From Baseline in 6-Minute Walk Distance (6MWD) at Week 72 - Modified Intention-to-treat (mITT) Population Measure: DB Period: Change From Baseline in 6MWD at Week 72 - Intent-to-Treat (ITT) Population Measure: DB Period: Average Rate of Change From Baseline in 6MWD at Week 72 - mITT Population Measure: DB Period: Average Rate of Change From Baseline in 6MWD at Week 72 - ITT Population.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change from baseline of FVC (forced vital capacity) at 26 weeks. After: Measure: Absolute Change From Baseline in Forced Vital Capacity for 26 Weeks Measure: Percent Change in Forced Vital Capacity From Baseline to Week 26 Measure: Absolute Change From Baseline in Forced Vital Capacity (% Predicted) Measure: Relative Change From Baseline in Percent Predicted Forced Vital Capacity From Baseline to Week 26 Measure: Semiannual Rate of Decline of Disease Activity Based on Forced Vital Capacity.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Incidence of Treatment-Emergent Adverse Events (Safety & Tolerability). After: Measure: Incidence of Treatment-Emergent Adverse Events.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Frequency of Adverse Events in Part 1 Measure: Percentage of Participants with Adverse Events in Part 1 Measure: Frequency of Injection Site Reactions in Part 1 Measure: Percentage of Participants with Injection Site Reactions in Part 1 Measure: Frequency of Adverse Events of Special Interest (AESIs) in Part 1 Measure: Percentage of Participants with Adverse Events of Special Interest (AESIs) in Part 1 Measure: Geometric Mean Titers (GMTs) of MERS-CoV Antigen Specific Binding Antibodies in Part 1 Measure: Percentage MERS-CoV Antigen Specific Neutralizing Antibodies in Part 1 Measure: Percentage Antigen Specific Cellular Immune Response in Part 1 Measure: Percentage of Seroconverted Participants in Part 1 Measure: Percentage of Participants with Overall Immune Response in Part 1 Measure: Frequency of Adverse Events in Part 2 Measure: Percentage of Participants with Adverse Events in Part 2 Measure: Frequency of Injection Site Reactions in Part 2 Measure: Percentage of Participants with Injection Site Reactions in Part 2 Measure: Frequency of Adverse Events of Special Interest (AESIs) in Part 2 Measure: Percentage of Participants with Adverse Events of Special Interest (AESIs) in Part 2 Measure: Geometric Mean Titers (GMTs) of MERS-CoV Antigen Specific Binding Antibodies in Part 2 Measure: Percentage MERS-CoV Antigen Specific Neutralizing Antibodies in Part 2 Measure: Percentage Antigen Specific Cellular Immune Response in Part 2 Measure: Percentage of Seroconverted Participants in Part 2 Measure: Percentage of Participants with Overall Immune Response in Part 2. After: Measure: Part 1: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs), Graded by Severity, and Treatment-related AEs Measure: Part 1: Percentage of Participants With Injection Site Reactions Measure: Part 1: Percentage of Participants With Adverse Events of Special Interest (AESIs) Measure: Part 1: Geometric Mean Concentration (GMC) of INO-4700 Antigen Specific Binding Antibody at Week 6 Measure: Part 1: Geometric Mean Fold Rise (GMFR) of INO-4700 Antigen Specific Binding Antibody at Week 6 Measure: Part 1: Geometric Mean Concentration (GMC) of INO-4700 Antigen Specific Binding Antibody at Week 10 Measure: Part 1: Geometric Mean Fold Rise (GMFR) of INO-4700 Antigen Specific Binding Antibody at Week 10 Measure: Part 1: Percentage Neutralizing Antibody Responders at Week 6 Measure: Part 1: Percentage Neutralizing Antibody Responders at Week 10 Measure: Part 1: Percentage of Antigen Specific Cellular Immune Responders at Week 6 Measure: Part 1: Percentage of Antigen Specific Cellular Immune Responders at Week 10 Measure: Part 2: Percentage of Participants With Adverse Events Measure: Part 2: Percentage of Participants With Injection Site Reactions Measure: Part 2: Percentage of Participants With Adverse Events of Special Interest (AESIs) Measure: Part 2: Geometric Mean Concentration (GMC) of INO-4700 Antigen Specific Binding Antibody Measure: Part 2: Percentage Neutralizing Antibody Responders Measure: Part 2: Percentage of Antigen Specific Cellular Immune Responders.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Efficacy of ADX-324 in preventing investigator-confirmed HAE attacks. After: Measure: Efficacy of ADX-324 in preventing HAE attacks.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Best overall response (BOR). After: Measure: Objective response rate (ORR).
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: (Part A) Change in Aortic Valve Calcium (AVC) from baseline to Week 24 Measure: (Part B Dual-Primary) Percent change in AVA as measured by echocardiogram from baseline to Week 48 Measure: (Part B Dual-Primary) Change in peak VO2 from baseline to Week 48. After: Measure: (Part A) Change in Aortic Valve Calcium (AVC) score as assessed by non-contrast CT from baseline to Week 24 Measure: (Part B Dual-Primary) Percent change in Aortic Valve Area (AVA) as measured by echocardiogram from baseline to Week 48 Measure: (Part B Dual-Primary) Change in peak VO2 by CPET from baseline to Week 48.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Objective Response Rate Measure: Prolongation of Overall Survival (OS) with NAI Therapy by ALC Response. After: Measure: ORR, defined as Investigator-assessed CR + PR per RECIST v1.1. Measure: Prolongation of OS with NAI therapy by ALC response, where: - OS is defined as the time from first study drug administration to death resulting from any cause. - ALC response is defined as achievement or maintenance of an on-treatment ALC ≥ 1,000 cells/μ.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Percent change in body weight (main study) Measure: Nature, frequency and severity of AEs (study extension) Measure: Part C - The nature, frequency, and severity of treatment-emergent adverse events (TEAEs), including serious adverse events (SAEs) and adverse events of special interest (AESIs). After: Measure: Percent change in body weight (main study) Measure: Nature, frequency and severity of AEs (study extension).
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Proportion of Participants With Smoking Abstinence During the Last 4 Weeks of 6 Weeks Cytisinicline Treatment Versus Placebo Treatment (Wk 3-6) Measure: Proportion of Participants With Smoking Abstinence During the Last 4 Weeks of 12 Weeks Cytisinicline Treatment Versus Placebo Treatment (Wk 9-12). After: Measure: Percentage of Participants With Smoking Abstinence From Weeks 3 to Week 6 Measure: Percentage of Participants With Smoking Abstinence From Weeks 9 to Week 12.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Proportion of Participants With Vaping Abstinence During Weeks 9 to 12. After: Measure: Percentage of Participants With Vaping Abstinence From Week 9 to 12.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Safety and tolerability as measured by number of/incidence of Adverse Events (AEs), including AESI and SAEs. Measure: Safety and tolerability as measured by the number of incidence/MRI abnormalities.. After: Measure: Safety and Tolerability as Measured by Number of/Incidence of Treatment-expected Adverse Events (TEAE) and Treatment-related Adverse Events (AEs). Measure: Safety and Tolerability as Measured by Number of/Incidence of Adverse Events of Special Interest and Serious Adverse Events Measure: Safety and Tolerability as Measured in Evaluation of Vital Signs, Clinical Laboratory Results and Findings From Physical, Neurological, Ophthalmological Examinations and Electrocardiograms. Measure: To Evaluate the Long-term Safety and Tolerability of AL002 Utilizing the Columbia-Suicide Severity Rating Scale (C-SSRS) Measure: To Evaluate the Effect of Dose Titration on ARIA-E Measure: To Evaluate the Effect of Dose Titration on ARIA-H.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Primary Composite Endpoint. After: Measure: Clinical Endpoint.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Pharmacokinetics: Cmax Measure: Pharmacokinetics: AUC0-tau Measure: Pharmacokinetics: CL/F. After: Measure: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Measurable Concentration (AUC0-last) of Berotralstat Measure: Area Under the Plasma Concentration-Time Curve From Time 0 to 6 Hours Post-dose (AUC0-6) of Berotralstat Measure: Concentration at the End of the Dosing Interval (Ctrough) of Berotralstat Measure: Maximum Observed Plasma Concentration (Cmax) of Berotralstat Measure: Time of Last Measurable Plasma Concentration (Tlast) of Berotralstat Measure: Time to Maximum Plasma Concentration (Tmax) of Berotralstat.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Percent change in body weight. After: Measure: Percent change in body weight (main study) Measure: Nature, frequency and severity of AEs (study extension) Measure: Part C - The nature, frequency, and severity of treatment-emergent adverse events (TEAEs), including serious adverse events (SAEs) and adverse events of special interest (AESIs).
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Percent Change from Baseline in Fasting Triglycerides (TG) at Month 10. After: Measure: Percent Change From Baseline at Month 10 in Fasting Triglycerides (TG).
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Efficacy measured as the change from Baseline in inflammatory nodule/abscess count at Week 12.. After: Measure: Change From Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 12.
14 in January 2026. Primary completion date moved later while its type (estimated or actual) stayed the same. Largest move first.
Before: 30 Jun 2026. After: 30 Sep 2027.
Before: 29 Jul 2026. After: 31 Jul 2027.
Before: 1 Dec 2027. After: 1 Dec 2028.
Before: 31 Mar 2026. After: 30 Nov 2026.
Before: 31 Dec 2026. After: 30 Jun 2027.
Before: 31 Dec 2025. After: 1 Jun 2026.
Before: Nov 2025. After: Jun 2026.
Before: Jul 2026. After: Dec 2026.
Before: Dec 2025. After: Feb 2026.
Before: Sep 2026. After: Oct 2026.
Before: 31 Mar 2026. After: Oct 2026.
Before: Aug 2025. After: 20 Nov 2026.
Before: Jan 2026. After: Dec 2027.
Before: Mar 2026. After: Aug 2026.
5 in January 2026. Primary completion date moved earlier while its type stayed the same. Largest move first.
Before: 30 Nov 2028. After: 30 Jun 2028.
Before: 31 Aug 2027. After: 30 Jun 2027.
Before: 23 Mar 2020. After: 16 Mar 2020.
Before: Oct 2029. After: Jan 2029.
Before: Jan 2028. After: Jun 2026.
23 in January 2026. The participant count changed. Planned and actual counts are shown as recorded. Newest first.
Before: 1400 participants (planned). After: 1076 participants (actual).
Before: 100 participants (planned). After: 77 participants (planned).
Before: 125 participants (planned). After: 365 participants (planned).
Before: 900 participants (planned). After: 905 participants (actual).
Before: 30 participants (planned). After: 45 participants (planned).
Before: 110 participants (planned). After: 119 participants (actual).
Before: 40 participants (planned). After: 14 participants (actual).
Before: 174 participants (actual). After: 150 participants (actual).
Before: 50 participants (planned). After: 70 participants (planned).
Before: 665 participants (planned). After: 480 participants (planned).
Before: 92 participants (planned). After: 99 participants (actual).
Before: 1410 participants (planned). After: 1276 participants (planned).
Before: 152 participants (planned). After: 136 participants (actual).
Before: 198 participants (actual). After: 197 participants (actual).
Before: 120 participants (planned). After: 152 participants (planned).
Before: 330 participants (planned). After: 990 participants (planned).
Before: 360 participants (planned). After: 343 participants (actual).
Before: 8 participants (planned). After: 1 participants (actual).
Before: 201 participants (planned). After: 206 participants (actual).
Before: 350 participants (planned). After: 91 participants (actual).
Before: 300 participants (planned). After: 316 participants (actual).
Before: 400 participants (planned). After: 480 participants (planned).
Before: 300 participants (planned). After: 320 participants (planned).
27 in January 2026. Any other change of recruitment status, such as recruiting to completed. Newest first.
Before: Active not recruiting. After: Completed.
Before: Recruiting. After: Active not recruiting.
Before: Not yet recruiting. After: Recruiting.
Before: Recruiting. After: Active not recruiting.
Before: Not yet recruiting. After: Recruiting.
Before: Not yet recruiting. After: Recruiting.
Before: Not yet recruiting. After: Recruiting.
Before: Not yet recruiting. After: Recruiting.
Before: Not yet recruiting. After: Recruiting.
Before: Not yet recruiting. After: Recruiting.
Before: Not yet recruiting. After: Recruiting.
Before: Recruiting. After: Active not recruiting.
Before: Not yet recruiting. After: Recruiting.
Before: Recruiting. After: Active not recruiting.
Before: Not yet recruiting. After: Recruiting.
Before: Active not recruiting. After: Completed.
Before: Not yet recruiting. After: Recruiting.
Before: Not yet recruiting. After: Recruiting.
NCT05339126 · NeuroPace
Before: Recruiting. After: Active not recruiting.
Before: Recruiting. After: Completed.
Before: Active not recruiting. After: Completed.
Before: Recruiting. After: Active not recruiting.
Before: Recruiting. After: Active not recruiting.
Before: Not yet recruiting. After: Recruiting.
Before: Recruiting. After: Active not recruiting.
Showing 25 of 27. Browse all tracked trials to open the rest.
TrialRedline, “Clinical trial registry changes: January 2026”. https://trialredline.com/reports/2026-01
Based on public ClinicalTrials.gov record history. How we collect and check the data